June 27, 2012

Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The addition of cetuximab to first-line chemotherapy seems to benefit patients with KRAS G13D-mutant tumors. Relative treatment effects were similar to those in patients with KRAS wild-type tumors but with lower absolute values.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Tejpar et al. (Wed,) studied this question.

synapsesocial.com/papers/69dca88ea5c75be4cfe5352c https://doi.org/https://doi.org/10.1200/jco.2012.42.2592

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Evaluation of Individual Codon 12 and 13 Mutant (MT) KRAS Alleles as Prognostic and Predictive Biomarkers of Response to Panitumumab (pmab) in Patients with Metastatic Colorectal Cancer (mCRC)2011 · 23 citations
2Abstract 955: Specific forms of mutant <i>KRAS</i> predict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancer2011 · 1 citations
3Genome-scale analysis of aberrant DNA methylation in colorectal cancer2011 · 602 citations
4Electrostatic control of GTP and GDP binding in the oncoprotein p21ras1996 · 54 citations
5Mutant <i>KRAS</i> Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab2012 · 233 citations

Preguntar a la IA

Me gusta

Guardar